Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Disclosures: MAD consulted for Amgen, Janssen-Cilag, and Takeda; received travel expenses from Janssen-Ortho and Genesis Pharmaceuticals; received honoraria from Amgen, Novartis, Celgene, Takeda, Genesis Pharmaceuticals, Janssen-Cilag, and BMS; and received research funding from Janssen-Cilag and Amgen. JS-M served on an advisory board for Takeda, Celgene, Novartis, Amgen, Janssen-Cilag, BMS, and MSD. DW received honoraria from and consulted for Amgen, BMS, Celgene, Janssen, and Takeda. LB received honoraria from and consulted for Celgene, Takeda, Janssen, and Amgen. GC received honoraria from and consulted for Janssen, Celgene, Takeda, and BMS; served on a speakers bureau for Janssen, Celgene, and Takeda; received research funding from Takeda and Celgene, and; and received travel expenses from Janssen and Takeda. PJH served on an advisory board for Amgen, BMS, Celgene, Janssen, Novartis, and Takeda. PM consulted for Celgene, Takeda, Janssen, Novartis, and Amgen; and received honoraria from Celgene, Takeda, Novartis, Janssen-Cilag, and Amgen. JLK consulted for Amgen, Roche, BMS, Seattle Genetics, Sutro Biopharma, and Pharmacyclics; and received research funding from Amgen and Novartis. HJS served on an advisory board for Janssen, Celgene, and Amgen. M Lalancette received honoraria from BMS and Celgene. SI received honoraria from Janssen, Celgene, Ono Pharmaceutical, Novartis, and BMS; and consulted for Janssen, Celgene, Ono Pharmaceutical, Takeda, BMS, Sanofi, Chugai Pharma, Kyowa Hakko Kirin, Novartis, Astellas Pharma, and Toyama Chemical Co. HMP received honoraria and travel expenses from Janssen, Celgene, Amgen, Novartis, and Takeda. T Cochrane received travel expenses from BMS, Novartis, Celgene, and Takeda. AO received honoraria from and consulted for Amgen, Takeda, and Janssen; and served on a speakers bureau for Amgen and Janssen. NJB received honoraria and travel expenses from Celgene, Takeda, Janssen, and Amgen; served on advisory boards for Celgene, Takeda, Janssen, and Amgen; served on speakers bureaus for Celgene, Janssen, and Amgen; received research funding from and provided expert testimony to Celgene and Janssen. AC consulted for Array BioPharma, Celgene, Novartis, Millennium, Amgen, Janssen Oncology, and BMS; received travel expenses from Takeda, Celgene, Novartis, Amgen, Janssen Oncology, and BMS; and received research funding from Array BioPharma, Celgene, Millennium, Novartis, Onyx, Janssen, Pharmacyclics, Acetylon Pharmaceuticals, Biotest, and BMS. LO, JMS, T Casneuf, CC, and DS are employees of Janssen. KW is a former employee of Janssen and is currently an employee of Celgene. AKS is a former employee of Janssen and is currently employed at Genesis Pharmaceuticals. NZK is a former employee of Janssen and is currently employed at Autolus. LO, JMS, T Casneuf, and AKS hold equity in Johnson & Johnson. H-AL received honoraria from and served on speakers bureaus for Celgene, Amgen, BMS, Sanofi, and Janssen; and received research funding from Celgene and Janssen. SZU consulted for Celgene, Amgen, and Janssen Oncology; served on a speakers bureau for Celgene, Takeda, and Amgen; and received research funding from Celgene, Millennium, Onyx, Array BioPharma, Janssen Oncology, Pharmacyclics, and Sanofi. AB, M Leiba, JM, KK, NT, HM, and JSK have no conflicts of interest to disclose.

Contributions: All authors were involved in the study design and/or data interpretation, and drafting, critically reviewing, and revising the manuscript. MAD, JS-M, AB, DW, LB, GC, MeravL, JM, PJH, KK, NT, PM, JLK, HJS, MarcL, HM, SI, JSK, HMP, TaraC, AO, NJB, AC, HA-L, and SZU contributed to the accrual and treatment of patients. LO’R, KW, JMS, TinekeC, CC, DS, AKS, and NZK collected and analyzed the data. All authors approved submitting the manuscript for publication, and being accountable for the accuracy and integrity of the study.